Elevation Oncology terminates license for EO-3021 after prior development discontinuation

Elevation Oncology, Inc.

Terminated License Agreement with CSPC Megalith Biopharmaceutical effective June 26, 2025.
License originally granted July 27, 2022, for worldwide rights to EO-3021 (Claudin 18.2 ADC) outside China.
Development of EO-3021 was discontinued on March 20, 2025; termination follows that decision.
All licensed IP reverts to CSPC; mutual release of claims with no further payments due.

item 1.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.